{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:36:02Z","timestamp":1784856962127,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.annder.2026.103488","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:48:19Z","timestamp":1776865699000},"page":"103488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systematic skin cancer screening in patients treated with biologics for chronic inflammatory rheumatic diseases: an 11-year experience"],"prefix":"10.1016","volume":"153","author":[{"given":"C.","family":"Elbaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lombart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-7110","authenticated-orcid":false,"given":"B.","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Arnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Potereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pagniez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Doussiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Goeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0172-2892","authenticated-orcid":false,"given":"G.","family":"Chaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2026.103488_b0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2026.103488_b0010","first-page":"8","article-title":"Recommendations for using TNF\u03b1 antagonists and French clinical practice guidelines endorsed by the French National Authority for Health","volume":"81","author":"Go\u00ebb","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.annder.2026.103488_b0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2026.103488_b0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0025","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0030","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheunm"},{"key":"10.1016\/j.annder.2026.103488_b0035","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.annder.2026.103488_b0040","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0045","first-page":"2615","article-title":"Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systematic review and meta-analysis","volume":"40","author":"Liu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.annder.2026.103488_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.annder.2026.103488_b0055","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.annder.2026.103488_b0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site-specific cancers in TNF alpha inhibitor treated patients with rheumatoid arthritis and other arthritides\u2014a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0065","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/sim.2580","article-title":"A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.annder.2026.103488_b0070","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2013"},{"key":"10.1016\/j.annder.2026.103488_b0075","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/ard.2004.029199","article-title":"Prevalence of rheumatoid arthritis in France: 2001","volume":"64","author":"Guillemin","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0080","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/annrheumdis-2013-204436","article-title":"Prevalence of spondylarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort","volume":"74","author":"Costantino","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101692","article-title":"The epidemiology of psoriatic arthritis: a literature review","volume":"35","author":"Karmacharya","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.annder.2026.103488_b0090","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2026.103488_b0095","first-page":"727","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0100","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annder.2026.103488_b0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/bjd\/ljae201","article-title":"Incidence and trends of first basal cell carcinomas in France between 1980 and 2019: a regional population-based registry study","volume":"191","author":"Hammas","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2026.103488_b0110","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.annder.2026.103488_b0115","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/ijc.34606","article-title":"Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis","volume":"153","author":"Wang","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annder.2026.103488_b0120","first-page":"12","article-title":"Non-melanoma skin cancer increases in the elderly","volume":"40","author":"Krader","year":"2019","journal-title":"Dermatol Times"},{"key":"10.1016\/j.annder.2026.103488_b0125","unstructured":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. Volume 1-Tumeurs solides. Institut national du cancer, Sant\u00e9 publique France. Sant\u00e9 publique France; 2019. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/cancers\/cancer-du-sein\/documents\/rapport-synthese\/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-metropolitaine-entre-1990-et-2018-volume-1-tumeurs-solides-etud (last accessed July 10 2025)."},{"key":"10.1016\/j.annder.2026.103488_b0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2026.103488_b0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological DMARDs in rheumatoid or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:44:45Z","timestamp":1781124285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963826000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0151963826000220"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2026.103488","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic skin cancer screening in patients treated with biologics for chronic inflammatory rheumatic diseases: an 11-year experience","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2026.103488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103488"}}